



2022 Interim Results


Asymchem Laboratories (Tianjin) Co., Ltd.

002821.SZ/6821.HK

- This document is not for public dissemination and the information contained herein is for the exclusive use of the persons to whom it is addressed and their advisers in connection with Asymchem Laboratories (Tianjin) Co., Ltd. (the “Company”, together with its subsidiaries, hereinafter referred to as the “Group”). It is being made available by the Company to a limited number of recipients. The contents of this document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and whoever comes into possession of this document should inform themselves about, and observe such restrictions. Any failure to comply with this restriction may constitute a violation of the United States, Canadian, PRC or Japanese securities laws or the laws of any such other jurisdictions. By accepting this document, you agree to be bound by the foregoing limitations.
- Forward-Looking Statement
- This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients’ intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.
- All financials disclosed in this document are presented in accordance with International Financial Reporting Standards (“IFRS”s) except for those specifically noted otherwise.
- Use of Adjusted Financial Measures
- We have provided adjusted net profit attributable to shareholders of the Company and adjusted net profit margin attributable to shareholders of the Company as additional financial measures, which are not required by, or presented in accordance with, the IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that we do not consider indicative of the performance of our business. However, the presentation of these non- IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS.

Contents

- 1 Performance Overview
- 2 Business Highlights
- 3 Financial Performance
- 4 Prospect in Second Half





1

Performance Overview



Strong Revenue and Profit Growth in 1H 2022

Revenue
(RMB mm)

50.34

↑ +186.7%

Gross Profit
Margin

46.9%

↑ +2.2%

↑ +305.3%

1,740

Net Profit Attributable to
Owners of the Company
(RMB mm)

↑ +244.8%

1,537

Adjusted Net Profit
(RMB mm)

↑ +10.1%

34.6%

Net
Profit Margin

↑ +5.1%

30.5%

Adjusted Net Profit
Margin

1,470

Backlog
(USD mm)

↑ +59.5%

8,900+

Number of
Employees

Backlog
(USD mm)

1,245

Small Molecule
CDMO Business


225

Emerging
Business

↑ +274.0%

Basic EPS
(RMB/Share) **4.75**

Accelerating Growth on Back of “Dual-Wheel-Drive” Strategy



Small Molecule CDMO Business

- ✓ The revenue of small molecule CDMO business was RMB4,637mm, with **187.6%** period on period growth
- ✓ 254 projects have been completed, with **41.9%** period on period growth, of which 48 Phase III clinical projects have been completed, with **33.3%** period on period growth
- ✓ Over **35** domestic NDA stage orders in hand

Emerging Business

- ✓ Revenue generated from emerging business was RMB393mm, with **174.2%** period on period growth
- ✓ **476** projects have been completed in 1H 2022, with period on period **321.2%** growth
- ✓ Multiple segments in emerging business recording a revenue growth of **200%+**

Delivery of Large Orders

- ✓ Successfully delivered the large orders during the reporting period
- ✓ For large orders, the Company recognized a revenue of RMB3.03 billion during 1H

Market Enlargement

- ✓ Actively developed “new markets、new businesses and new customers”
- ✓ Put more efforts in early-stage projects reserves
- ✓ Cooperated deeply with cutting-edge biotech companies

System Upgrade

- ✓ Set up the business divisions and groups; vigorously built a global talent platform
- ✓ Executed strict cGMP quality system and comprehensive EHS management and QA system
- ✓ Improved the supply chain management system


Technology Advancement

- ✓ Flow and continuous technology and biological enzyme technologies applied for about 40% of Phase II and later clinical projects
- ✓ Ramps up the cooperation model of continuous reaction technology export
- ✓ Over **4,000** R&D employees and **8** technology platforms provided strong technical support for the development of new layout and direction.

Large Orders Stimulated Revenue in 1H 2022



(RMB100 mm)



Robust Revenue from All Types of Customers, Domestic Market Ushered in the Harvest Period



Strong customer stickiness: 2018-1H 2022,
we **achieved a 100% retention ratio** of our top 20 customers



Partner of Choice for Blue-chip Customers


- ☞ The Company adheres to the strategy of “deeper service for large customers”, improves the cooperation stickiness and service depth to large pharmaceutical companies in Europe and America, and gradually extends the service chain when seizing the strategic opportunity brought by large orders and expanding new customers and projects.
- ☞ we provided lean quality management for a commercial API product to secure its continuous and stable production, and thus the **first pass yield** and **on-time delivery** of the product. Strongly promoted the Company’s cooperation with multinational pharmaceutical companies in commercial API projects.
- ☞ The revenue for above commercial API project recognized in 1H 2022 was RMB3.03 billion.
- ☞ Working with **15** of the 20 largest pharmaceutical companies in the world, among which **8** have done business with us for **10+** consecutive years.




Empowering Global Small- and Medium-Sized Pharmaceutical Companies

- ☞ As small- and medium-sized customers invest more in future R&D and many favorable policies such as MAH are introduced, small- and medium-sized customers are expected to be **one of the main drivers for our future growth**.
- ☞ The Company adheres to the strategy of “wider services ” for small- and medium-sized customers and domestic customers, and continuously serves more customer groups, especially small- and medium-sized innovative drug companies.
- ☞ The company cooperated deeply with cutting-edge biotech companies with advanced technology service capabilities, which helped the accumulation of the scale effect of knowledge and a **sustainable increase in revenue** from overseas small and medium-sized innovative drug companies.

Robust Revenue from All Types of Customers



Domestic Market Ushered in the Harvest Period




Talent Team Fosters Rapid Development of the Company




Continuous Improvement of Employee Structure and Echelon

No. of Employees



No. of R&D Employees



Attract Overseas High-end Talents
Optimize Organizational Structure

110

Introduction of top talents in 1H 2022

including

53

Doctors

37


overseas returnees and foreign talents

Board of Scientific Advisors

Board of Development Strategy Advisors

- ✓ Provide **world-class** technical guidance
- ✓ Participating in the **evaluation and appraisal** and acceptance of the Company's R&D projects
- ✓ Explore **domestic market**
- ✓ Improve the professional and scientific level of the Company's strategic decision-making

Stable Increase in Number of Employees



2016-2021 Revenue CAGR: **33.3%**

Revenue increased by **186.7%** as compared with that in 1H 2021, and the no. of employees increased by **59.5%** during the same period

2


Business Highlights



Accelerated Growth of Small Molecule CDMO Business



Continued Improvement of Projects Quantity and Service Pipelines




- ✓ Intensify the exploration of early stage projects, with abundant project reserves, and lay foundation for long-term growth
- ✓ Involve **20+** popular targets or major drug targets, such as KRAS, 3CL,JAK, TYK2, etc., with projects accounting for more than **60%**
- ✓ The number of commercial stage projects increased steadily, resulting in **367.4%** period on period revenue growth

Working More on New Market Expansion Asia-Pacific Markets Pace into Harvest Period


- ✓ Seize the opportunity from large orders and accelerate the exploration of diversified, multi-regional and multi-stage markets
- ✓ Made positive progress in domestic market, and the Company had a number of mature projects efficiently completing dynamic verification. We made a revenue of **RMB382mm** in domestic market during the reporting period, realizing a period on period growth of **260.0%**
- ✓ After assisting the Hutchison Whampoa with its Surufatinib project successfully launched in China, the Company continued to provide relevant services for its U.S. NDA project. **2 new NDA** projects we served successfully passed the on-site verification of NMPA.

Revenue From Small Molecule CDMO Business



Gross Profit at Commercial Stage

Gross Profit at Clinical Stage




Active Expansion in Small Molecule Manufacturing Capacity



10

Capacity of Small Molecule CDMO (Traditional Reactor)



Application of Continuous Reaction Technology in Scale Production

- ✓ The **area** of the continuous reaction workshop increased by more than **70%** period on period
- ✓ The number of continuous **equipment** increased by nearly **75%** period on period
- ✓ The continuous reaction **capacity** increased by nearly **400%** period on period

cost

TJ1, cGMP Production
West District under
Construction

Tianjin 2
Headquarter, R&D Vase

Tianjin 3
R&D and cGMP Production

Fuxin 1
cGMP & RSMs Production

Fuxin 2
RSMs Production

Dunhua 1
cGMP and non GMP
Production

Dunhua 2
cGMP and non-GMP
Production

Dunhua 3
cGMP and non-GMP
Production
under Construction

Suzhou
R&D Center
under Construction

Yangtze River Delta
cGMP and non GMP
Production
Under Construction

Boston
R&D Center &
Sales Center

North Carolina
Sales Center

Snapdragon
Flow and Continuous
Technology CDO

3


1

London
Sales Center


Blooming of Emerging Business




Expand our skills and experience in small molecule CDMO to those of other drugs



Revenues from Emerging Business





Gross Profit for Emerging Business



Rapid Development of Chemical Macromolecule Business



We provide comprehensive CDMO solutions for oligonucleotides, polymers, payload-linkers, polypeptides and other chemical macromolecules.



Number of new projects exceeds **20**, including RDC precursors, PDC, lipids, dendrimers, etc
Expanded several commercial lipid GMP stocks
Added **3** new Isolators for OEB5 and cytotoxic production



Talent Team

300+ Process Developers
(30+ with PhD)

300+ Analysts, Engineers,
QA and RA



Customers
& Projects

10+ new customers were developed,
nearly **50** new contracts signed

27+ projects were advanced to Phase
II among the





Revenue

Revenue: **211.1%** + period on period

Revenue from Oligonucleotides :
200%+ period on period

Construction completion of the R&D center of approximately 12,000m² and the GMP production plant of approximately 9,500 m² by the end of 2022

Drug product Business has Entered Fast Lane



Set up the Center for Drug Delivery and Formulation (CDDF).



focused on the research and development of cutting-edge drug delivery and high-end formulations



provide technical support to domestic and global customers for the benefit of patients



Ensure the "safety" of drug.

Revenue

+79.6%
period on period

Backlog Overseas

+100%
period on period

New Projects

100+
(Including 10+ NDA projects)

Small Nucleic Acid

+376%
period on period

CRO Business Accelerated the Listing of New Drugs



The Company's CRO business (Clin-nov Medical) is an important link for R&D and manufacturing of new drugs, and the Company's CDMO+CARO provides one-stop services from IND to DNA.


Construction of Operation Capacity

Clin-nov Medical and Improve Quality quickly established good business collaboration after realizing team integration

Established a subsidiary of Clin-nov in Boston, launched the construction of clinical operation capacity in the US

Built a Board of Scientific Advisors comprised, and independently developed a number of clinical trial information systems

Assisted China's first independently Developed oral small molecule treatment drug for COVID-19 to be conditionally marketed



650+ employees

+62.5% from end of 2021

Talent Team

170+new projects, including over 85% innovative drug projects

50+ clinical phase projects on oncology, immunity, anti-infection and infection diseases

Customers & Projects

Backlog: RMB450 mm+

Revenue : 242.4% period on period growth

Orders and Revenue

Undertook a number of integrated service projects from CMC, pharmacodynamics, pharmacology and toxicology to pre-clinical IND registration and application and the Sino-US double report projects, realizing one-stop comprehensive services for the whole life cycle of innovative drugs

Speed up the Construction of Biologics CDMO Capacity , Driving the Delivery of Projects



Jinshan Factory (Shanghai)



- Pilot R&D, toxicology batch, IND/clinical sample/commercial plants covering protein, mAb, ADC and other products

Fengxian Commercial Base (Shanghai)



- Commercial production capacity construction and layout of antibody (mAb and double antibody) ;
- Commercial production capacity construction and layout of ADC products

Xinsufang & BioBay (Suzhou)



- Plasmid (PD+GMP) pilot and commercialization;
- mRNA/LNP (PD+GMP) pilot and commercialization;
- Viral vector (PD+GMP) pilot and clinical

Capacity construction of 2x2000L disposable bioreactor antibody stock solution



The pilot plant for 100L ADC coupling stock solution has been put into operation



2x500L commercial ADC coupling stock solution will be put into operation at the end of September

Commercial base advanced in an orderly manner

Construction is to be started in the second half of the year

Plasmid and mRNA business pilot capacity have been put into operation



Be capable of IND and clinical samples preparation



Backlog: Over RMB260mm





Complete Delivery of First IND Project

Began to Recognize Revenue

Biosynthesis Technology Continued to Promote



Since the establishment of the CSBT in 2021, the Company has a mature enzyme technology platform and fermentation production platform, and continues to explore the synthetic biotechnology field to significantly enhance the platform's technical capabilities



Technology Exploration

Created technology platform for high-throughput screening and engineering modification of chassis microorganisms

Pharmaceutical protein technology platform upgrades the means of therapeutic protein preparation by creating an efficient inclusion body protein preparation process

Track Records in Reporting Period

Undertaken process characterization projects for BLA

R&D and production project in the later clinical stage









Completed the GMP production orders

Widespread Orders

engineered enzymes, recombinant proteins, medicinal enzymes...

Help customers to screen target enzymes with specific catalytic activity, which have received good feedback and evaluation.

Eight R&D Centers Striving to Perform Customer-centered Innovation



Advanced Technological Platform

CEPS : The Company has accumulated **700+** R&D projects, designed **90+** synthetic routes, developed **11** new routes and applied for **12** patents during the reporting period

CFCT : The area of the continuous reaction workshop increased by more than **70%** period-on-period, the number of continuous equipment increased by nearly **75%** period-on-period, and the continuous reaction capacity increased by nearly 400% period-on-period, and applied for **5** patents during the reporting period

CSBT : Company has developed nearly **2,400** engineered enzyme libraries, **800+** of which are conferred with IP rights of the Company, covering **20+** species, and applied for **9** patents during the reporting period

CIMT : The digital design of flow-based process was successfully selected into the Ministry of Industry and Information Technology's List of **Excellent Scenarios for Intelligent Manufacturing in 2021**

Eight Technology Platforms : Build a new engine for **one-stop GXP services** of Asymchem "GMP-GLP-GCP".

Continuous R&D Investment

RMB263 mm of R&D investment in 1H 2022, with **60.7%** period on period growth, accounting for **5.2%** of revenue

Advantages of Flow and Continuous Technology




Flow and continuous technology converts traditional batch manufacturing process into an automatic continuous process



Continuous manufacturing is considered by the USFDA as “one of today’s most important tools for modernizing the pharmaceutical industry”

USFDA recommends pharmaceutical companies to apply this manufacturing technology and issued a draft guidance “Quality Considerations for Continuous Manufacturing: Guidance for Industry” in 2019

We are one of the **earliest** organizations in the world to apply continuous technology to drug manufacturing and one of the few companies to successfully deploy it in **ton-scale drug manufacturing**



Antiviral drug

Production Cycle

Scale up from **gram- to tonne-scale** in **6 months** of project launch

Production Steps

Consolidate **4** production steps into **1**



A customer

Technological advantages

From RSM process optimization to tonnage API validation production within **8 Months**

Time advantages

Assist customers in completion of project within **18 months**





3


Financial Performance




Key Financial Indicators Doubled or More in the Reporting Period

Various key financial indicators doubled or more in 1H 2022, including the revenue, Gross Profit and Gross Profit Margin, net profit attributable to owners of the parent company and adjusted net profit attributable to owners of the parent company.


Revenue




Gross Profit and Gross Profit Margin



Net Profit Attributable to Owners of the company



Adjusted Net Profit Attributable to Owners of the company




Segment Revenue




All segments are booming and developing rapidly. On the basis of continuously providing high-quality services to major customers, the Company enhanced the coverage of diversified customers both in domestic and abroad and expanded market share.


Commercial Stage CDMO Solutions




Clinical Stage CDMO Solutions




Emerging Business



Revenue by Customer Type



Revenue by Customer Region



Revenue and Gross Profit @CER



(RMB100 mm)	1H 2022	1H 2021	Growth Rate	1H 2022 @CER	Growth Rate*
Revenue	50.34	17.56	186.7%	50.23	186.1%
Gross Profit	23.63	7.85	200.9%	23.57	200.1%
Gross Profit Margin	46.9%	44.7%	2.2%	46.9%	2.2%


*1H 2022@CER vs.1H 2021

@CER (Constant Exchange Rate). In 2021, approximately 86.2% of our revenue was paid in currencies other than RMB. Our financial statements are recorded in RMB, so the exchange rates will significantly affect our financial performance. Therefore, we believe that excluding the influence of exchange rate fluctuations on operating revenue and gross profit margin in the reported results is helpful in analyzing and comparing indicators at different periods. This constant monetary information assumes that the same effective exchange rates as in the year-ago period are adopted to convert the current period results.


Segment Gross Profit and Gross Profit Margin




Commercial Stage CDMO Solutions



Clinical Stage CDMO Solutions



Emerging Business





(RMB mm)

Gross profit margin @CER Gross profit margin

Capital Expenditure




% of Revenue



(RMB100 mm)


Efficient application of fixed assets, high value added per capita income, and continuous increase in R&D investment



Adjusted Net Profit



(RMB mm)	1H 2022	1H 2021
Net Profit Attributable to Owners of the company	1,740	429
Plus:		
Equity incentive amortization expense	35	15
Gain or loss on exchange rate fluctuations	(273)	4
Gains on forward settlement and sale of foreign currency	(1)	-
Income tax effect	36	(2)
Adjusted Net Profit Attributable to Owners of the company	1,537	446



4

Prospect in Second Half



International Standards



Chinese Advantages

Technical Driver



Green Orientation

Continuation of
Technology and
Experience in
Small Molecule Business

Pushing Forward the New
Business Segment Expansion



Taking advantage of the “large order” to extend the scope of services and expand new markets and businesses.



Pushing for the development of new business segments in full swing to inject strong momentum into the Company.



Making more efforts to promote the application of new technologies, and leading technological innovation based on the eight technology centers.



Continuously upgrading the efficiency of R&D and production, further reducing costs to enhance our overall competitiveness.



Comprehensively enhancing the talent strategy and creating a multi-dimensional talent cultivation system.

Appendix



INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME



RMB mm

	1H 2022	1H 2021
REVENUE	5,034	1,755
Cost of sales	(2,671)	(970)
Gross profit	2,363	785
Other income and gains	347	99
Selling and distribution expenses	(51)	(40)
Administrative expenses	(350)	(199)
Research and development expenses	(263)	(164)
(Losses on)/reversal of impairment of financial and contract assets, net	(53)	8
Other expenses	(6)	(6)
Finance costs	(8)	-
Share of profits/(losses) of Associates	9	(1)
PROFIT BEFORE TAX	1,988	482
Income tax expense	(248)	(53)
PROFIT FOR THE PERIOD	1,740	429
Plus:		
Equity incentive amortization expense	35	15
Gain or loss on exchange rate fluctuations	(273)	4
Gains on forward settlement and sale of foreign currency	(1)	-
Income tax effect	36	(2)
Adjusted Net Profit Attributable to Owners of the company	1,537	446

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION



RMB mm

	1H 2022	2021
NON-CURRENT ASSETS		
Property, plant and equipment	4,064	3,336
Right-of-use assets	484	363
Goodwill	146	146
Other intangible assets	65	63
Deferred tax assets	251	187
Investments in associates	301	292
Prepayments, deposits and other receivables	317	355
Financial assets at fair value through profit or loss	102	104
Total non-current assets	5,730	4,846
CURRENT ASSETS		
Inventories	1,901	1,396
Trade receivables	3,104	1,816
Contract assets	1	1
Prepayments, deposits and other receivables	411	458
Tax recoverable	3	4
Financial assets at fair value through profit or loss	919	401
Cash and bank balances	5,765	6,234
Total current assets	12,104	10,310
Total assets	17,834	15,156

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (continued)



RMB mm

	1H 2022	2021
CURRENT LIABILITIES		
Trade payables	873	552
Other payables and accruals	1,591	1,201
Interest-bearing bank and other borrowings	-	375
Lease liabilities	12	13
Tax payable	186	64
Amounts due to related parties	169	-
Total current liabilities	2,831	2,205
NET CURRENT ASSETS	9,273	8,105
TOTAL ASSETS LESS CURRENT LIABILITIES	15,003	12,951
NON-CURRENT LIABILITIES		
Other payables and accruals	175	179
Lease liabilities	52	46
Deferred tax liabilities	190	116
Total non-current liabilities	417	341
Net assets	14,586	12,610
EQUITY		
Share capital	370	263
Restricted shares under share-based payment	(467)	(482)
Other reserves	14,683	12,829
Total equity	14,586	12,610